Director, Quantitative Clinical Pharmacology
Sarepta Therapeutics, United States
Tao is currently a director of Quantitative Clinical Pharmacology at Sarepta Therapeutics.
Tao has accumulated more than 10 years of drug development experiences for various modalities with a focus on rare genetic diseases and pediatric drug development with increasing responsibilities at Sarepta Therapeutics, Vertex Pharmaceuticals, Pfizer, and Merck. As the Quantitative Clinical Pharmacology lead, he has made significant contributions to the approval of three drug products including ELEVIDYS® (gene transfer therapy for Duchenne Muscular Dystrophy), TRIKAFTA® (small molecule triple combination for Cystic Fibrosis) and NGENLA® (recombinant fusion protein for Pediatric Growth Hormone Deficiency) in various regions. Tao has extensive clinical experiences in nucleic acid therapeutics, including peptide conjugated antisense oligonucleotide, antibody conjugated siRNA, lipid nanoparticle encapsulated mRNA, highlighted by multiple industry white papers on these modalities.
In addition to his Quantitative Clinical Pharmacology role, Tao has being leading the steering committe for professional conferences in the Cell, Gene, RNA and Gene Editing therapy space in Greater Philadelphia since 2022, aiming to bring together key stakeholders (innovators, business leaders, service providers, policy makers, regulators and investors) in the region and leverage their resources to raise the visibility of Greater Philadelphia’s well-developed biopharma and biotech ecosystem.
Disclosure information not submitted.
Applications and Challenges of MIDD in Nucleic Acid therapies
Sunday, October 19, 2025
11:00 AM - 12:30 PM MDT